Gut health and immunotherapy for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This trial studies how the gut (your digestive system) affects how well immunotherapy works for advanced liver cancer. You'll have a colonoscopy (a test to look inside your bowel) and provide samples, which could help doctors improve treatment for you and others.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have hepatocellular carcinoma (liver cancer) that is advanced or cannot be removed with surgery.
- You must be receiving standard immunotherapy treatment (often called immune checkpoint inhibitors).
- You should not have a chronic intestinal disease like inflammatory bowel disease or celiac disease.
- You must not have taken antibiotics within the last 4 to 6 weeks before joining.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether changing the bacteria in your gut (with a probiotic) can help your current immunotherapy work better if your liver cancer has been growing. It's for people with advanced liver cancer who will continue their same immunotherapy despite the cancer progressing.
This study looks at how the bacteria in your gut (microbiome) might affect treatment for liver cancer. It tests a combination of targeted therapy and immunotherapy, which are already approved for liver cancer. The goal is to see if gut bacteria can predict how well the treatment works.
This study looks at how the bacteria in your gut (microbiome) affect liver cancer treatment. It aims to learn if certain gut bacteria can predict how well the combination of targeted therapy and immunotherapy works.
This trial tests whether transplanting healthy stool bacteria into your gut can help your own immune system fight liver cancer that has stopped responding to the standard first combination treatment (atezolizumab + bevacizumab). It is for patients whose liver cancer has started growing quickly despite that treatment.
This trial studies whether a fecal microbiota transfer (a “gut bacteria transfer” from a donor) can help liver cancer patients overcome resistance to atezolizumab and bevacizumab. It aims to improve how well the standard medicines control the cancer.
This trial tests whether giving a fecal transplant (a procedure that replaces the bacteria in your gut) can help people with advanced liver cancer whose current treatment has stopped working. It may help boost your immune system to fight the cancer.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.